

**ASX Announcement | 08 June 2021**  
**Visioneering Technologies (ASX:VTI)**

## **Retirement of Director**

**Atlanta, Georgia, Monday, 07 June 2021 (Tuesday, 08 June 2021 Sydney time):** US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, **Visioneering Technologies, Inc (ASX: VTI)** (**'Visioneering'** or **'the Company'**), announces the retirement of Mr Tom Dooley as a non-executive director of the Company, effective today, immediately following the closing of the Annual Meeting of Stockholders.

Mr Dooley has been a non-executive director of the board since 01 May 2017, and has provided invaluable service to VTI during his tenure.

"Those of us who know and have worked with Tom admire him for his business acumen and his commitment to VTI and its shareholders," said Dr. David J. Mazzo, non-executive Chairman of the VTI Board of Directors. "On behalf of all of the members of the Board as well as the employees of VTI, I thank Tom for his service and contributions and wish him well in the future."

**Ends.**

**This release was authorized by the CEO, Stephen Snowdy, PhD**

**For more information, please contact:**

<b><i>Company</i></b>	<b><i>Investor and media relations</i></b>
Stephen Snowdy, PhD CEO, Visioneering Technologies, Inc. E: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Simon Hinsley NWR Communications M: +61 401 809 653 E: <a href="mailto:simon@nwrcommunications.com.au">simon@nwrcommunications.com.au</a>

### **About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is a health care company making innovative vision care products available to patients and eye care professionals. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from the healthcare industry to provide new solutions for adults and children in need of vision correction.

Headquartered in the United States, Visioneering designs, manufactures, sells and distributes contact lenses around the world. Its flagship product, NaturalVue® Multifocal contact lenses, are prescribed in the large addressable markets of nearsighted children and over-45 adults, and VTI is expanding its portfolio of technologies to address a range of other vision care needs. Since its IPO in 2017, the company has grown operations across the US and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada, and Europe.

### **Foreign ownership restrictions**

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.